Alternative targeted therapy for early HER2 positive breast cancer

Harvey, Sandra L. and Khasraw, Mustafa 2013, Alternative targeted therapy for early HER2 positive breast cancer, Gland surgery, vol. 2, no. 1, pp. 42-45, doi: 10.3978/j.issn.2227-684X.2013.02.06.

Attached Files
Name Description MIMEType Size Downloads

Title Alternative targeted therapy for early HER2 positive breast cancer
Author(s) Harvey, Sandra L.
Khasraw, MustafaORCID iD for Khasraw, Mustafa
Journal name Gland surgery
Volume number 2
Issue number 1
Start page 42
End page 45
Total pages 4
Publisher Gland Surgery
Place of publication [unknown]
Publication date 2013-02
ISSN 2227-684X
Summary Her2 (erbB2) receptor is overexpressed in around twenty percent of early breast cancer and historically conferred a poorer prognosis (1). Targeted anti-Her2 therapy has significantly improved outcomes for these women.
Language eng
DOI 10.3978/j.issn.2227-684X.2013.02.06
Field of Research 111203 Cancer Genetics
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Persistent URL

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 395 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Tue, 07 May 2013, 15:15:26 EST by Jane Moschetti

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact